GlassScriptPhysician profile
Nonglin Mel
NPI 1760619993
$18,162.63
in general payments reported to CMS, 2019-2025
13 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $180 · 2021: $1,945 · 2022: $1,653 · 2023: $834 · 2024: $1,287 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,100 · Food and Beverage: $4,526 · Travel and Lodging: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,100.00 |
| Food and Beverage | $4,525.79 |
| Travel and Lodging | $1,759.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,186.09 | 2020-2025 | Descovy, Yeztugo, Biktarvy |
| Viiv Healthcare Company | $3,851.59 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $931.06 | 2020-2022 | |
| Janssen Products, LP | $398.08 | 2021-2022 | |
| Abbvie INC. | $282.20 | 2022 | |
| Merck Sharp & Dohme LLC | $163.31 | 2022-2025 | Pifeltro, Capvaxive, Delstrigo |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Breztri |
| Emd Serono, INC. | $112.41 | 2024-2025 | |
| Theratechnologies INC. | $30.09 | 2023 | Trogarzo, Egrifta |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Ionis Pharmaceuticals, INC. | $21.04 | 2025 | Tryngolza |
| Pfizer INC. | $18.90 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nonglin Mel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.